The Canadian Hematology Consensus Group, or CHCG, is a national collaboration of Canadian hematologists and healthcare professionals dedicated to improving patient care through the development of National consensus recommendations in hematologic malignancies.

Our most recent consensus paper has been published in Current Oncology. The paper provides treatment recommendations for hematologists managing patients with relapsed and/or refractory FL. In this episode, we will discuss the content of the paper with Dr Lemieux, who is a lead author and a member of the CHCG scientific committee.

Our Guest

Dr Lemieux is a Hematologist at the CHU de Québec-Université Laval in Quebec city, Quebec and a Canadian expert in the treatment of follicular lymphoma.

This podcast episode has been funded by Merck Canada.

Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology. In this video, Dr. Owen highlights the group’s multidisciplinary expert panel, rigorous methodology, and current initiatives, including consensus papers on relapsed/refractory follicular lymphoma and first-line diffuse large B-cell lymphoma.

The CHCG was founded by Anna Christofides, President of IMPACT Medicom Inc. and Founder & Managing Director of the CHCG, to provide the scientific and operational infrastructure required to develop high-quality Canadian consensus recommendations and support knowledge translation in hematology.

Learn more about the CHCG:
www.canadianconsensusgroup.com

In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap.

Our guest

Dr. Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre and Alberta Blood and Marrow Transplant Program. He is also a clinical assistant professor at the University of Calgary. Dr Puckrin has received honoraria for advisory boards and/or speaking engagements from Abbvie, Astrazeneca, BeOne, Eli Lilly, Incyte, Kite, Janssen,Pfizer, Roche, and Seagen.

Please provide your feedback on this episode by filling out this quick survey at the following link: https://survey.decipherinc.com/survey/selfserve/53b/g00e/2511135

Funding for this episode was provided by Eli Lilly Canada.

This information is intended solely for educational purposes and is not intended to promote the use of any Eli Lilly Canada medication. All materials or information provided by Eli Lilly Canada Inc. for this learning program comply with applicable regulatory standards.​

Editorial control of this learning program resides with the speaker within the parameters of the Innovative Medicines Canada Code and Eli Lilly Policy.

Eli Lilly Canada supports discussion of its products consistent with the approved prescribing information in the product monograph.

Any off-label discussion of products represents the personal opinion of the speaker.​